NasdaqGS:GERNBiotechs
Geron (GERN) Q1 Loss Sharply Narrows And Tests Skeptical Profitability Narratives
Geron (GERN) opened 2026 with Q1 revenue of US$51.8 million, a basic EPS loss of US$0.005, and net income loss of US$3.6 million. This set the tone for another earnings season where growth and profitability stay in focus. Over the last year the company has seen revenue move from US$76.9 million in Q4 2024 to US$196.1 million on a trailing twelve month basis, while the trailing basic EPS loss narrowed from US$0.27 to US$0.10. This leaves investors weighing ongoing losses against improving...